The Journal of Experimental Medicine
StemCell Technologies
  Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Citation Map
Services
Right arrow Email this article
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new content in the JEM
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Djerbi, M.
Right arrow Articles by Grandien, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Djerbi, M.
Right arrow Articles by Grandien, A.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
© The Rockefeller University Press, 0022-1007/1999/10/1025/ $5.00
The Journal of Experimental Medicine, Volume 190, Number 7, October 4, 1999 1025-1032

The Inhibitor of Death Receptor Signaling, FLICE-inhibitory Protein Defines a New Class of Tumor Progression Factors

Mounira Djerbia, Valentina Screpantia, Anca Irinel Catrinab, Bjarne Bogenc, Peter Biberfeldb, and Alf Grandiena
a Department of Immunology, Wenner-Gren Institute, University of Stockholm, S-10691 Stockholm, Sweden
b Immunopathology Laboratory, Institute for Oncology-Pathology, the Karolinska Institute and Hospital, S-17177 Stockholm, Sweden
c Institute of Immunology, National Hospital, University of Oslo, N-0172 Oslo, Norway

Correspondence to: Alf Grandien, Dept. of Immunology, the Wenner-Gren Institute, University of Stockholm, S-10691 Stockholm, Sweden. Tel:46-8-16-41-78 Fax:46-8-15-41-63 E-mail:alf.grandien{at}imun.su.se.

Death receptor–mediated apoptosis can be modulated by several antiapoptotic proteins, such as the FLICE (FADD [Fas-associated death domain]-like IL-1ß–converting enzyme)-inhibitory proteins (FLIPs). The FLIP family includes both cellular and viral members. The Kaposi's sarcoma–associated herpesvirus protein (KSHV)-FLIP is expressed by human herpesvirus 8 (HHV-8), which is associated with malignancies such as Kaposi's sarcoma and certain lymphomas. In this paper, we demonstrate that KSHV-FLIP protects cells from Fas-mediated apoptosis by inhibiting caspase activation and permits clonal growth in the presence of death stimuli in vitro. Furthermore, we show that KSHV-FLIP can act as a tumor progression factor by promoting tumor establishment and growth in vivo. When injected into immunocompetent recipient mouse strains, murine B lymphoma cells (A20) transduced with KSHV-FLIP rapidly develop into aggressive tumors showing a high rate of survival and growth. The tumor-progressive activity of KSHV-FLIP is mediated by prevention of death receptor–induced apoptosis triggered by conventional T cells. Consequently, inhibitors of death receptor signaling can be regarded as a new class of tumor progression factors, and HHV-8–associated tumors may represent naturally occurring examples of the tumorigenic effect of such inhibitors.

Key Words: apoptosis, Fas receptor, antiapoptotic proteins, herpesvirus, lymphoma


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:



  Home | Help | Feedback | Subscriptions | Archive | Search
TABLE OF CONTENTS